Head-to-head evidence
BPI-361175 vs SH-1028
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BPI-361175
Developed by Betta Pharmaceuticals Co.
NCT05329298 · Phase 1/2 · status unknown
This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.
SH-1028
Developed by Nanjing Sanhome Pharmaceutical
NCT04239833 · Phase 3 · status unknown
In this randomized, double-blind, active-controlled Phase 3 trial in patients with EGFR-mutated non-small-cell lung cancer, SH-1028 significantly extended progression-free survival compared with gefitinib, the standard EGFR-targeted therapy (median 19.3 months vs 9.8 months).
Next expected readout: February 2028 · NCT06080776 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPI-361175's landscape · SH-1028's landscape